Casticin: A Promising Candidate to Develop a Stem Cell Targeted Strategy in AML Treatment

Volume: 4 Number: 3 September 1, 2020
  • Tugba Erkmen
  • Belgin Sert Serdar
  • Halil Ates
  • Pembe Keskinoglu
  • Semra Kocturk
EN

Casticin: A Promising Candidate to Develop a Stem Cell Targeted Strategy in AML Treatment

Abstract

Purpose: Acute myeloid leukemia is the most common form of acute leukemia with genetic and epigenetic heterogeneity. Although current therapeutic agents provide successful remission, 5-year survival rates are still low. Insufficiency of targeting leukemia stem cells is considered as the main obstacle that causes drug resistance and relapse. Phytochemicals remain a promising source for targeted drug research. Studies showed that Casticin has antiproliferative effects on leukemic cells, but its effects on leukemic stem cells are still unclear. In this study, we aimed to investigate the antiproliferative capacity of Casticin on acute myeloid leukemia stem-like KG1a cells and its relatively mature parental KG1 cells in comparison with healthy peripheral blood mononuclear cells PBMC . Method: The antiproliferative effects of Casticin on cells and IC50 values were determined by MTT test. The effects of Casticin on caspase 3/7 activity, apoptosis and necrosis in cells were evaluated by flow cytometry and TUNEL assays. Results: 2 μM Casticin treatment for 24 h was increased apoptotic cell death and caspase 3/7 activation in KG1 27.2%; 17.30%; p

Keywords

References

  1. 1. Löwenberg B, Rowe JM. Introduction to the review series on advances in acute myeloid leukemia (AML). Blood 2016;127:1. [CrossRef]
  2. 2. Carraway HE. Improving overall survival in older adults with acute myeloid leukemia: subpopulations matter. Am Soc Clin Oncol 2018;36:3186–3188. [CrossRef]
  3. 3. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730–737. [CrossRef]
  4. 4. Darwish NHE, Mousa SA. Intrinsic targeting strategies against acute myeloid leukemic stem cells. Integr Cancer Sci Therap 2015. [CrossRef]
  5. 5. Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood 2017;129:1577–1585. [CrossRef]
  6. 6. Hu L, Cao D, Li Y, He Y, Guo K. Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors. Cancer Biol Ther 2012;13:516–526. [CrossRef]
  7. 7. Mahbub AA, Le Maitre CL, Haywood-Small SL, McDougall GJ, Cross NA, Jordan-Mahy N. Differential effects of polyphenols on proliferation and apoptosis in human myeloid and lymphoid leukemia cell lines. Anti-cancer Agents Med Chem 2013;13:1601– 1613. [CrossRef]
  8. 8. Zeng Y, Weng G, Fan J, et al. Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells. Oncology Rep 2016;36:1233–1242. [CrossRef]

Details

Primary Language

English

Subjects

-

Journal Section

-

Authors

Tugba Erkmen This is me

Belgin Sert Serdar This is me

Halil Ates This is me

Pembe Keskinoglu This is me

Semra Kocturk This is me

Publication Date

September 1, 2020

Submission Date

-

Acceptance Date

-

Published in Issue

Year 2020 Volume: 4 Number: 3

APA
Erkmen, T., Sert Serdar, B., Ates, H., Keskinoglu, P., & Kocturk, S. (2020). Casticin: A Promising Candidate to Develop a Stem Cell Targeted Strategy in AML Treatment. Journal of Basic and Clinical Health Sciences, 4(3), 297-304. https://doi.org/10.30621/jbachs.2020.1226
AMA
1.Erkmen T, Sert Serdar B, Ates H, Keskinoglu P, Kocturk S. Casticin: A Promising Candidate to Develop a Stem Cell Targeted Strategy in AML Treatment. JBACHS. 2020;4(3):297-304. doi:10.30621/jbachs.2020.1226
Chicago
Erkmen, Tugba, Belgin Sert Serdar, Halil Ates, Pembe Keskinoglu, and Semra Kocturk. 2020. “Casticin: A Promising Candidate to Develop a Stem Cell Targeted Strategy in AML Treatment”. Journal of Basic and Clinical Health Sciences 4 (3): 297-304. https://doi.org/10.30621/jbachs.2020.1226.
EndNote
Erkmen T, Sert Serdar B, Ates H, Keskinoglu P, Kocturk S (September 1, 2020) Casticin: A Promising Candidate to Develop a Stem Cell Targeted Strategy in AML Treatment. Journal of Basic and Clinical Health Sciences 4 3 297–304.
IEEE
[1]T. Erkmen, B. Sert Serdar, H. Ates, P. Keskinoglu, and S. Kocturk, “Casticin: A Promising Candidate to Develop a Stem Cell Targeted Strategy in AML Treatment”, JBACHS, vol. 4, no. 3, pp. 297–304, Sept. 2020, doi: 10.30621/jbachs.2020.1226.
ISNAD
Erkmen, Tugba - Sert Serdar, Belgin - Ates, Halil - Keskinoglu, Pembe - Kocturk, Semra. “Casticin: A Promising Candidate to Develop a Stem Cell Targeted Strategy in AML Treatment”. Journal of Basic and Clinical Health Sciences 4/3 (September 1, 2020): 297-304. https://doi.org/10.30621/jbachs.2020.1226.
JAMA
1.Erkmen T, Sert Serdar B, Ates H, Keskinoglu P, Kocturk S. Casticin: A Promising Candidate to Develop a Stem Cell Targeted Strategy in AML Treatment. JBACHS. 2020;4:297–304.
MLA
Erkmen, Tugba, et al. “Casticin: A Promising Candidate to Develop a Stem Cell Targeted Strategy in AML Treatment”. Journal of Basic and Clinical Health Sciences, vol. 4, no. 3, Sept. 2020, pp. 297-04, doi:10.30621/jbachs.2020.1226.
Vancouver
1.Tugba Erkmen, Belgin Sert Serdar, Halil Ates, Pembe Keskinoglu, Semra Kocturk. Casticin: A Promising Candidate to Develop a Stem Cell Targeted Strategy in AML Treatment. JBACHS. 2020 Sep. 1;4(3):297-304. doi:10.30621/jbachs.2020.1226

Cited By